Table 3.
Univariate analyses of recurrence-free survival and overall survival in 218 hepatocellular carcinomas
| Variable | Recurrence-free survival |
Overall survival |
||
|---|---|---|---|---|
| HR (95% CI) p-value | HR (95% CI) p-value | |||
| Age (≤ 55 yr vs. > 55 yr) | 0.908 (0.659-1.253) | 0.558 | 1.104 (0.751-1.623) | 0.614 |
| Gender (female vs. male) | 0.999 (0.667-1.495) | 0.996 | 1.307 (0.777-2.198) | 0.312 |
| Tumor size (≤ 5.0 cm vs. > 5.0 cm) | 1.721 (1.252-2.366) | 0.001 | 2.487 (1.694-3.653) | < 0.001 |
| Edmondson grade (I+II vs. III) | 1.621 (1.130-2.327) | 0.009 | 1.709 (1.113-2.623) | 0.014 |
| Microvascular invasion (no vs. yes) | 2.396 (1.723-3.332) | < 0.001 | 3.608 (1.996-4.716) | < 0.001 |
| Major portal vein invasion (no vs. yes) | 3.045 (1.545-5.999) | 0.001 | 5.249 (2.620-10.517) | < 0.001 |
| Intrahepatic metastasis (no vs. yes) | 4.154 (2.935-5.879) | < 0.001 | 5.870 (3.946-8.732) | < 0.001 |
| Multicentric occurrence (no vs. yes) | 1.382 (0.677-2.821) | 0.374 | 0.611 (0.194-1.925) | 0.400 |
| AJCC T-stage (1 vs. 2+3+4) | 2.534 (1.814-3.540) | < 0.001 | 3.266 (2.103-5.072) | < 0.001 |
| BCLC stage (0+A vs. B+C) | 2.072 (1.511-2.841) | < 0.001 | 3.084 (2.067-4.600) | < 0.001 |
| Albumin level (> 3.5 g/dL vs. ≤ 3.5 g/dL) | 1.845 (1.193-2.855) | 0.006 | 2.463 (1.508-4.022) | < 0.001 |
| AFP level (≤ 200 ng/mL vs. > 200 ng/mL)a) | 1.502 (1.089-2.072) | 0.013 | 1.325 (0.895-1.962) | 0.159 |
| Etiology (non-viral vs. viral) | 2.674 (1.447-4.941) | 0.002 | 1.463 (0.783-2.733) | 0.233 |
| Liver cirrhosis (no vs. yes) | 1.307 (0.954-1.790) | 0.095 | 1.099 (0.750-1.613) | 0.628 |
| PEG10 expression (- vs. +) | 2.041 (1.425-2.921) | < 0.001 | 1.859 (1.186-2.914) | 0.007 |
HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; PEG10, paternally expressed gene 10.
a)
Partial data were not available.